Novel Asthma Biomarkers to Predict the Response to Inhaled Corticosteroid
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Tongji Hospital
- Enrollment
- 148
- Locations
- 1
- Primary Endpoint
- Change from baseline airway epithelial cytokines expression, FEV1 and methacholine PD20 at 4 and 8 weeks
Study Overview
Brief Summary
Novel asthma biomarkers to predict the response to inhaled corticosteroid Brief description: This will be a single center study of asthmatic subjects and healthy controls which will investigate mechanisms underlying different response to inhaled corticosteroid, the mainstay of asthma therapy. Only about half of the asthmatic patients have improved lung function after treatment of inhaled corticosteroid. The investigators hypothesize that there are biomarkers such as epithelial cytokines (IL-25, IL-33, TSLP) in airway tissues or plasma of asthmatic patients which could predict the response of asthmatic patients to inhaled corticosteroid. Finding novel asthma biomarker will help the clinicians to choose the optimal treatment for individual asthmatic patient.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Male and female subjects between the ages of 18 and 70 years
- •No respiratory symptoms
- •Normal spirometric value and methacholine PD20 >2.5mg
- •Inclusion Criteria:
- •Male and female subjects between the ages of 18 and 70 years
- •History of asthma
- •No use of oral or inhaled corticosteroids for the treatment of asthma
- •No use of leukotriene antagonist for the treatment of asthma
- •Hyperreactivity to methacholine (PD20 FEV1 Methacholine < 2.5 mg) and/or ≥12% increase in FEV1 following inhalation of 200μg salbutamol
- •Asthma symptoms of episodic cough, wheeze and/or breathlessness
Exclusion Criteria
- •Current or former smokers
- •Pregnant women
- •Subjects with a history of lung disease other than asthma
- •Subjects with a history of a medical disease, which in the opinion of the investigator may put the subject at extra risk from study-related procedures or because the disease may influence the results of the study
Arms & Interventions
Asthmatics (treatment)
Steroid-naïve asthma, randomized to inhaled budesonide, 2 puffs (200mcg) twice a day for 8 weeks. These subjects will undergo bronchoscopy and induced sputum collection at baseline, undergo pulmonary function testing and peripheral blood collection at baseline, 4 and 8 weeks after treatment with inhaled corticosteroids.
Intervention: Budesonide (Drug)
Outcomes
Primary Outcomes
Change from baseline airway epithelial cytokines expression, FEV1 and methacholine PD20 at 4 and 8 weeks
Time Frame: 8 weeks
1. The baseline expression of airway epithelial cytokines (IL-25, IL-33, TSLP) and/or Th2 cytokines (IL-4, IL-5, IL-13) in bronchial brushing, bronchial biopsy and peripheral blood in healthy control subjects and asthmatic patients. 2. Change of forced expiratory volume of the 1st second (FEV1) and accumulated dosage of methacholine provoking a 20% fall of in forced expiratory volume in the first second (FEV1 PD20) of asthmatic patients after treatment with inhaled budesonide or non-intervention for 4 and 8 weeks.
Secondary Outcomes
No secondary outcomes reported
Investigators
Guohua Zhen, MD
Professor
Tongji Hospital